Last reviewed · How we verify

NCT05079100

Effectiveness of Counseling on Use of Postpartum Family Planning.

Completed NA Last updated 23 January 2024
What this trial tests

NA trial testing postpartum contraception method counselling in Contraceptive Usage in 120 participants. Completed in 20 May 2022.

Timeline
1 February 2022
Primary endpoint
1 March 2022
20 May 2022

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment120
Start date1 February 2022
Primary completion1 March 2022
Estimated completion20 May 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 15 to 49, female only, with Contraceptive Usage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Family planning (FP) is the most supported, reasonable public health service to prevent both maternal and newborn mortality and decrease the risk of adverse maternal, perinatal, and infant outcomes. The World Health Organization's (WHO) recommend of waiting at least 2 years after a live birth before attempting the next pregnancy as short interval between pregnancies increase risk of preterm labor; low birth weight; fetal, early neonatal and infant death; and serious maternal outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Contraceptive Usage

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05079100.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing